Iktos announced research alliance with Almirall for new drug design

By Nikita Chaurasia  Date: 2019-12-14

Iktos announced research alliance with Almirall for new drug design
  • The new drug design to involve AI technology for optimization of advanced compounds and boosting up the identification if drug candidates for Almirall drug discovery program.
  • The agreement is likely to provide rapid identification of molecules for the satisfaction of multiple bioactivity for clinical trials.
  • Under the pact, Almirall would leverage Iktos’s AI accuracy to bring about a difference in the patients’ lives.

One of the prominent AI companies dealing in novel drug design, Iktos, has reportedly announced establishing a research partnership with leading skin-health focused pharmaceutical company, Almirall on the grounds of designing novel drug compounds via the use of Iktos’ AI technology.

As per reliable reports, Iktos’ AI technology offers high speed and efficiency to the drug discovery process through automatically designing virtual molecules that display desirable characteristics of an advanced drug candidate. This is apprehended to tacked one of the fundamental challenges in drug design which is the rapid and repetitive identification of molecules that authenticate the multiple bioactive attributes for testing.

On this acquisition, the executive Vice president R&D and Chief Scientific Officer of Almirall, Dr. Bhushan Hardas was quoted stating that the collaboration serves as an example of how the company intends to explore myriad possibilities served by the technology to discover new molecules and boost the clinical development. He further added that the company has planned to stand at the forefront of innovations to build holistic and transversal approaches in the medical field. AI is anticipated to offer Almirall a distinctive opportunity to amalgamate its skills with an intent to augmenting patients’ lives.

Meanwhile, the president and CEO of Iktos, Yann Gaston- Mathe, cited that the company is delighted to be partnered with Almirall as this collaboration would bolster the leadership position of the company in the domain of AI for new drug design. 

Iktos has of late announced umpteen collaborations and mergers with the biopharmaceutical companies where the company lays immense focus on accelerating the design of promising compounds.

Source credit: https://finance.yahoo.com/news/iktos-almirall-announce-research-collaboration-080100761.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

By Nikita Chaurasia

Tech giant Apple, Inc. has recently unveiled the 16-inch MacBook Pro, which promises extraordinary design and performance. The model can be customized with the all-new M1 Pro and M1 Max processors.    These new 10-core processors are ...

Kedrion Biopharma expands to North America with Prometic acquisition

Kedrion Biopharma expands to North America with Prometic acquisition

By Nikita Chaurasia

Prometic Life Sciences has developed the first FDA-approved treatment for Congenital Plasminogen Deficiency. This acquisition will enable easy access to advanced therapies for patients suffering from this rare disease. Kedrion Biopharma Inc. has...

Facebook Pages to reduce focus on Likes and followers for Indian users

Facebook Pages to reduce focus on Likes and followers for Indian users

By Nikita Chaurasia

Facebook Inc. has reportedly removed Likes from Facebook Pages for its Indian users to make the platform more user-friendly and easier to understand. This redesign of Facebook Pages was launched in January 2021 and has been rolled out for Indian user...

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

By Nikita Chaurasia

India is likely to witness a record number of IPOs this year, with several companies eyeing public listing to raise funds if the market sentiment remains positive. One such company, Pine Labs is reportedly planning to list itself on Nasdaq by October...

European climate group asks EU for tougher CO2 targets for truck makers

European climate group asks EU for tougher CO2 targets for truck makers

By Nikita Chaurasia

According to a recent study conducted by Europe’s Transport and Environment (T&E), the European Union (EU) should implement stricter CO2 targets for truck makers to swiftly transition to zero-emission models as present goals do not provide ...